Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
|ClinicalTrials.gov Identifier: NCT00445952|
Recruitment Status : Completed
First Posted : March 9, 2007
Last Update Posted : February 1, 2018
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
PURPOSE: This natural history study is collecting information about fungal infections of the blood over time from patients with cancer or from patients who have undergone a stem cell transplant.
|Condition or disease||Intervention/treatment|
|Cancer||Other: clinical observation Procedure: management of therapy complications|
- Determine the incidence of fungemia in relation to the number of admissions to the hospital in patients with solid tumor or hematologic malignancy or in patients who have undergone hematopoietic stem cell transplantation.
- Determine the fungal species distribution, prognostic factors for outcome, and crude and attributable mortality in patients also diagnosed with fungemia.
OUTLINE: This is a multicenter, nonrandomized, prospective study.
- Group A (no documented fungemia at study entry): Data regarding the number of patients with cancer or who have undergone hematopoietic stem cell transplantation, including those who develop documented fungemia, who are admitted to the hospital is collected for 2 years.
- Group B (documented fungemia at study entry): Fungal strains isolated from the initial positive blood culture are collected and undergo examination, including confirmation of species identification, susceptibility testing, and/or minimum inhibitory concentration determination. Data, including antifungal treatment, clinical and microbiological response to antifungal treatment (at 2, 4, and 12 weeks after diagnosis), and survival status, is collected for each documented fungemia episode* for up to 12 weeks after diagnosis of fungemia.
NOTE: *That occurs within a 2-year period.
PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||304 participants|
|Official Title:||Fungemia Survey in Cancer Patients|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||May 12, 2016|
- Relative incidence of fungemia
- Fungal species distribution
- Survival in patients with fungemia
- Mortality at 2, 4, and 12 weeks after diagnosis of fungemia
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00445952
|Institut Jules Bordet|
|Brussels, Belgium, 1000|
|CHU de Grenoble - Hopital de la Tronche|
|Grenoble, France, 38043|
|German Hodgkin's Lymphoma Study Group|
|Cologne, Germany, D-50931|
|Ospedale San Martino|
|Genoa, Italy, 16132|
|Hopital Cantonal Universitaire de Geneve|
|Geneva, Switzerland, CH-1211|
|Study Chair:||Oliver Cornely||German Hodgkin's Lymphoma Study Group|